Many sections of AltTox.org conclude with invited essays written by technical or policy experts in the field covered in that section. The writers, whose brief biographical sketches follow their essays, were all asked to express their views on how best to accelerate progress on developing, validating, and gaining regulatory acceptance of non-animal methods in the topics under consideration. These "Way Forward" commentaries address specific fields of toxicity testing (e.g, neurotoxicity testing), types of non-animal technology applied to toxicity testing (e.g. Quantitative Structure-Activity Relationships), and stakeholder policies or programs (e.g., the Interagency Coordinating Committee on the Validation of Alternative Methods). Also included are more broadly focused essays on Overarching Challenges and Opportunities. The commentators were under no obligation to address all aspects of a topic; indeed, many chose to address a few salient aspects of the subject matter. Their views do not necessarily reflect those of the AltTox Management Team.
Readers are invited to discuss these commentaries in the AltTox Discussion Forums that correspond to the topics in question. Also, readers interested in writing Way Forward commentaries should contact the Management Team at info@alttox.org. We would especially welcome offers to write commentaries on topics that currently have few or no commentaries. Moreover, we will regularly post new commentaries and archive older ones.
Toxicity Endpoints & Tests
Acute Systemic Toxicity
Eye Irritation/Corrosion
Genotoxicity/Carcinogenicity
Neurotoxicity
Pharmacokinetics & Metabolism
Repeated Dose/Organ Toxicity
Reproductive & Developmental Toxicity
Skin Irritation/Corrosion
Skin Sensitization
Emerging Technologies
Cell-based Technologies
Integrated Testing Strategies & Risk Assessment
Omics, Computational Biology & Bioinformatics
(Q)SAR
Programs & Policies
United States
Overarching Challenges & Opportunities
|
by Chad Sandusky